Literature DB >> 3919873

Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination.

S P Hanley, J Gumb, J T Macfarlane.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919873      PMCID: PMC1418296          DOI: 10.1136/bmj.290.6473.970

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  In-vitro activity of erythromycin against atypical mycobacteria.

Authors:  A Molavi; L Weinstein
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

2.  Erythromycin for BCG cold abscess.

Authors:  G Singh; M Singh
Journal:  Lancet       Date:  1984-10-27       Impact factor: 79.321

3.  Erythromycin in the management of troublesome BCG lesions.

Authors:  J T Power; I C Stewart; J D Ross
Journal:  Br J Dis Chest       Date:  1984-04

4.  Plasma and saliva concentrations for a new formulation of erythromycin stearate.

Authors:  N Berend; J Rutland; G E Marlin
Journal:  Curr Med Res Opin       Date:  1979       Impact factor: 2.580

  4 in total
  3 in total

1.  Pulmonary Mycobacterium kansasii infection successfully treated with a regimen containing erythromycin.

Authors:  P J Guest; M G Britton; H C Grundy; M D Yates
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

2.  Regional lymphadenitis following BCG vaccination.

Authors:  C Merry; R J Fitzgerald
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

3.  Isoniazid or rifampicin versus bacillus Calmette-Guérin (BCG).

Authors:  P A Camargos; J I Martins; M T Fonseca
Journal:  Indian J Pediatr       Date:  1991 Jan-Feb       Impact factor: 1.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.